The GLP-1 Ripple Effect: Second-Derivative Winners Beyond Eli Lilly and Novo Nordisk

Forget the Pharma Trade. The Real GLP-1 Alpha Is Elsewhere.

Ozempic changed everything. Not just for Eli Lilly shareholders — for the entire consumer economy.

We've been tracking the second-order effects of GLP-1 drugs for over a year now, and what surprised us most wasn't the scale of weight loss (though 15–22% average body weight reduction is remarkable). It was how profoundly these drugs alter what people buy, where they spend time, and how they think about their bodies. GLP-1 users don't just eat less. They exercise more. They buy fitness trackers. They sign up for gyms. They trade sweatpants for performance activewear. They book hiking trips instead of all-inclusive resorts.

Wall Street is still pricing GLP-1 as a pharma trade. That's a mistake. Eli Lilly and Novo Nordisk trade at nosebleed valuations — LLY at 55x forward earnings, NVO at 33x — and every analyst on the planet covers them. The real alpha is in the companies nobody's connecting to weight loss drugs. The gym chain seeing membership surges. The wearables company watching attach rates climb. The activewear brand benefiting from millions of newly active consumers.

This is the second-derivative trade. And we think it's one of the most mispriced themes in the market today.

The Numbers: How GLP-1 Users Actually Spend Differently

Let's start with the data, because this thesis lives or dies on whether consumer behavior changes are real and measurable. They are.

PwC's 2025 Consumer Health & Wellness Survey tracked spending patterns across 12,000 US adults, segmented by GLP-1 usage. The findings were striking. GLP-1 users increased spending on wearable electronics by 29% compared to the pre-medication baseline. Gym and fitness membership spending rose 18%. Athletic footwear and activewear purchases climbed 22%. Protein supplement spending jumped 26%.

On the other side of the ledger: sweet snack purchases fell 6.7%. Baked goods dropped 11%. Sugary beverage consumption declined 14%. Fast food visits among GLP-1 users dropped 9.2% — but here's what's interesting — fast casual restaurant spending actually increased 8%, suggesting users are trading up to healthier options rather than simply eating out less.

The fitness industry tells the story most clearly. The US gym and fitness market expanded by $6.8 billion in TAM between 2023 and 2025, and industry analysts at IHRSA attribute roughly 30–35% of new membership growth to the “GLP-1 activation effect” — previously sedentary individuals who begin exercising after starting weight loss medication. These aren't the hardcore CrossFit crowd who cycle through gym memberships every January. GLP-1 users show significantly higher 12-month retention rates (74% versus 62% for traditional new members) because the drug reduces the physical barriers that typically cause people to quit.

The Winners: Six Stocks Riding the GLP-1 Behavioral Shift

We've identified six publicly traded companies with the strongest exposure to GLP-1-driven consumer behavior changes. Crucially, each has a solid fundamental thesis independent of GLP-1 — the weight loss drug tailwind is incremental upside, not the entire investment case.

Life Time Fitness (LTH) — The Premium Play

Life Time is the most direct beneficiary of the GLP-1 fitness activation effect, and it's not even close. The company operates 175+ luxury athletic resorts with an average membership of $175/month — these are not Planet Fitness-style $10/month facilities. Life Time's demographic is affluent, health-conscious, 35–55-year-olds — precisely the population most likely to be prescribed GLP-1 drugs and most able to afford them (GLP-1s still cost $800–1,200/month without insurance).

Management directly addressed the GLP-1 tailwind on their Q3 2025 earnings call, noting that new member surveys showed 12% of joiners cited weight loss medication as a motivating factor for starting a fitness routine. Same-center revenue grew 18% year-over-year. The company trades at roughly 28x forward EBITDA, which is premium for fitness but reasonable given its unit economics: 45% EBITDA margins on mature clubs, $30M+ revenue per location, and a 10-year average membership tenure.

Planet Fitness (PLNT) — The Volume Play

If Life Time captures the premium end, Planet Fitness captures the mass market. At $15/month for a basic membership, Planet Fitness has the lowest barrier to entry in commercial fitness. The company operates over 2,600 locations and has been adding members at a rate that exceeded pre-COVID trends for six consecutive quarters.

The GLP-1 angle here is about first-time gym goers. Planet Fitness's “Judgement Free Zone” branding specifically targets people who feel intimidated by traditional gyms — a description that fits many GLP-1 users who are beginning to exercise for the first time after significant weight loss. The company reported net member additions of 1.8 million in 2025, up 22% from 2024. Franchise same-store sales grew 9.7%. And here's the kicker: Planet Fitness's asset-light franchise model means incremental members drop almost entirely to the bottom line.

Hims & Hers (HIMS) — The Distribution Play

Hims & Hers has been the most aggressive publicly traded company in capturing GLP-1 demand through its telehealth platform. The company began offering compounded semaglutide (a generic-equivalent version of Ozempic) through its platform in 2024 at a fraction of the branded price — roughly $199/month versus $1,000+ for brand-name Ozempic.

Revenue grew 77% year-over-year in Q3 2025, and the GLP-1 category quickly became the company's fastest-growing product line. HIMS stock rose over 200% in 2024–2025 on this momentum. The risk? The FDA's resolution of the Ozempic shortage could end the compounding loophole that allows HIMS to sell non-branded semaglutide. Management is hedging by building a broader weight management ecosystem — nutritional coaching, fitness plans, metabolic monitoring — that retains subscribers regardless of the compounding regulatory outcome. If they pull that off, HIMS becomes a weight management platform, not just a drug distributor.

Garmin (GRMN) — The Wearables Winner

That 29% increase in wearable electronics spending among GLP-1 users? Garmin is catching a disproportionate share. While Apple Watch dominates the mass market, Garmin owns the fitness-focused wearable segment — runners, cyclists, hikers, and increasingly, health-motivated consumers who want serious biometric tracking rather than a notification screen on their wrist.

Garmin's fitness segment revenue grew 28% year-over-year in 2025, with management calling out “health-motivated new users” as a growing customer cohort. The company's average selling price for fitness wearables is $350–500, significantly higher than Apple Watch SE, which positions Garmin in the premium, higher-margin tier. With zero debt, $1.8 billion in cash, and 22% operating margins, Garmin is the kind of boring-but-excellent compounder that benefits from the GLP-1 tailwind without depending on it.

On Holdings (ONON) — The Activewear Disruptor

On Holdings, the Swiss performance running brand, has been growing at 30%+ annually and taking share from Nike and Adidas in the premium athletic footwear and apparel market. The GLP-1 connection is straightforward: millions of newly active consumers need running shoes, workout clothes, and performance gear. They are not buying bargain brands. They are buying premium, because the same affluent demographic that can afford $1,000/month GLP-1 drugs is the demographic that buys $180 running shoes.

On's direct-to-consumer channel grew 43% year-over-year in 2025, and the brand's Net Promoter Score ranks highest among premium athletic footwear brands globally. The stock isn't cheap at 42x forward earnings, but revenue growth of 30%+ with expanding gross margins (now 60.2%) justifies a premium multiple. GLP-1 adoption adds another structural demand driver to an already-strong brand momentum story.

Lululemon (LULU) — The Lifestyle Transition

Lululemon occupies a unique position. The brand sits at the intersection of athletic performance and lifestyle — people wear Lululemon to the gym, but also to brunch, to the office, and on airplanes. For GLP-1 users who are losing significant weight and building new wardrobes, Lululemon is the aspirational brand they gravitate toward. The company's resale and exchange data shows a measurable uptick in customers buying down in sizes, then repurchasing at their new size within 6–12 months.

Lululemon's men's category grew 15% year-over-year in 2025, partly driven by GLP-1's strong uptake among men aged 35–55. International expansion (China, Europe) remains the primary growth engine, but the GLP-1 tailwind in North America is providing a much-needed boost to the domestic market where the brand had been showing signs of saturation.

The Losers: Who Gets Disrupted by the Ozempic Economy

Every structural shift creates losers, and the GLP-1 wave is no exception. Some sectors are already feeling the pressure. Others are in denial.

Snack and Processed Food Companies

The snack aisle is ground zero. GLP-1 drugs work partly by reducing cravings for high-calorie, high-sugar foods — the exact products that generate 60–70% of margins for companies like Mondelez, General Mills, and the Frito-Lay division of PepsiCo. A 6.7% decline in sweet snack purchases among 15 million GLP-1 users is already material. Scale that to 40 million users by 2030, and you're talking about a $4–6 billion annual revenue headwind for the US snack industry.

The smart companies are adapting. Nestle launched its “Vital Pursuit” line in 2024 — a range of high-protein, portion-controlled frozen meals and snacks specifically designed for GLP-1 users. The products emphasize protein density (to counteract the muscle loss that accompanies GLP-1-driven weight loss) and are packaged in smaller portions that match reduced appetites. It's early, but Vital Pursuit generated an estimated $280 million in first-year revenue, suggesting the “GLP-1 companion food” category is real and growing.

Companies that refuse to adapt — that keep pushing king-size candy bars and family-size chip bags to a shrinking audience — will face a slow, structural erosion of their core market. This is not a cliff. It's a downward slope over 5–10 years. But for companies already growing revenue at low-single-digit rates, losing even 2–3 percentage points of organic growth is the difference between modest compounder and value trap.

Bariatric Surgery

This one is straightforward. Why undergo gastric bypass surgery — a procedure that costs $20,000–35,000, requires weeks of recovery, and carries real surgical risk — when a weekly injection achieves comparable weight loss? Bariatric surgery volumes peaked in 2023 and declined an estimated 15–20% in 2024–2025, a trend that is accelerating as GLP-1 access expands. Companies and hospital systems with significant bariatric revenue exposure are seeing procedure mix shift away from weight loss surgery toward other specialties.

Fast Food Chains (With Caveats)

The picture here is more nuanced than headlines suggest. Yes, GLP-1 users visit fast food restaurants 9.2% less often. But the impact varies wildly by chain. McDonald's and similar burger-and-fries operators face the steepest traffic declines among GLP-1 users. Chipotle, by contrast, is seeing GLP-1 users increase visit frequency — the brand's protein-forward, customizable bowls are exactly what someone on GLP-1 wants: high protein, moderate calories, fresh ingredients. Cava, the Mediterranean fast-casual chain, reported similar trends.

The lesson for investors: don't short fast food broadly. Short the operators that can't or won't adapt their menus. Go long on the protein-forward, customizable concepts. The GLP-1 economy doesn't kill restaurants — it reshuffles who wins.

The Third-Order Effects You Haven't Considered

Here's where the GLP-1 thesis gets genuinely weird and fascinating. Beyond the obvious fitness and food impacts, there are third-order effects rippling through sectors that no consumer health analyst would normally cover.

Life Insurance Repricing

Life insurance premiums are priced on actuarial tables that assume a certain prevalence of obesity-related mortality. If 30–40 million Americans achieve sustained weight loss through GLP-1 drugs, the reduction in cardiovascular disease, type 2 diabetes, and certain cancers should materially improve mortality curves for the 35–65 age cohort. Reinsurance companies are already beginning to model this. Swiss Re published a research note in late 2025 estimating that widespread GLP-1 adoption could improve US life expectancy by 1.5–2.3 years, which would significantly reduce claims reserves. If this plays out, life insurance companies could release reserves, boosting book value and returns on equity. Names to watch: MetLife (MET), Prudential (PRU), and Principal Financial (PFG).

Airline Fuel Savings (Yes, Really)

This sounds like a joke, but the math checks out. The average US airline passenger weighs approximately 195 lbs. Fuel consumption is directly proportional to total aircraft weight. If tens of millions of frequent flyers lose 15–30 lbs on GLP-1 drugs, the cumulative weight reduction across hundreds of millions of annual passenger trips translates to measurable fuel savings. Airlines for America (A4A) estimates that every pound of passenger weight reduction saves US carriers roughly $100 million per year in aggregate fuel costs. A 20-lb average weight reduction across even 10% of the flying population would save the US airline industry $200–400 million annually in fuel. It's not a reason to buy Delta. But it's a marginal tailwind nobody is modeling.

Healthcare Cost Reduction

This is the biggest third-order effect by far. Obesity costs the US healthcare system an estimated $173 billion annually in direct medical spending, according to the CDC. GLP-1 drugs that reduce obesity prevalence should, in theory, reduce the downstream healthcare costs associated with diabetes management, cardiovascular procedures, joint replacements, sleep apnea treatment, and dozens of other obesity-related conditions.

The paradox for health insurers is timing. In the short term (1–3 years), GLP-1 drug costs increase total healthcare spending because the drugs themselves are expensive ($10,000–15,000/year per patient). In the long term (5–10+ years), the reduction in obesity-related comorbidities should more than offset the drug cost. Managed care organizations like UnitedHealth (UNH) and Elevance (ELV) are navigating this tension in real time — expanding GLP-1 coverage while betting on long-term cost savings.

The Oral GLP-1 Catalyst: Why 2026–2027 Changes Everything

Everything we've discussed so far is based on injectable GLP-1 drugs. Weekly injections. Specialized auto-injector pens. Cold-chain storage. For many potential users, that's a dealbreaker. Surveys consistently show that 20–30% of patients who would otherwise consider GLP-1 therapy decline because they are needle-averse. Another 15–20% cite the inconvenience of weekly injections as a reason for discontinuation within the first year.

That barrier is about to disappear.

Eli Lilly's orforglipron is the frontrunner. Unlike Novo Nordisk's earlier attempt at oral semaglutide (Rybelsus), which required specific dosing conditions (empty stomach, no food for 30 minutes, limited water) and showed inferior efficacy to the injectable form, orforglipron is a small-molecule, non-peptide GLP-1 agonist that can be taken like a normal pill. No fasting requirements. No absorption issues. Phase 3 results showed 14.7% weight loss at 72 weeks — competitive with injectable Mounjaro. Lilly is expected to file for FDA approval in 2026 with a potential launch in late 2026 or early 2027.

Morgan Stanley projects oral GLP-1s could expand the addressable patient population by 40–60%, potentially bringing total global users from roughly 25 million today to 70–100 million by 2030. For investors in second-derivative stocks, this is the most important catalyst on the horizon. Every behavioral shift we've documented — more gym memberships, more wearables, more activewear, less junk food — gets multiplied by a dramatically larger user base.

The timing matters for stock selection. Second-derivative plays like Life Time Fitness and Garmin have not yet priced in the oral GLP-1 expansion because the market still treats GLP-1 as primarily a pharma story. By the time oral pills launch and adoption data starts flowing through earnings, the multiple re-rating opportunity will have passed. We think the window to position is now.

The Bear Case: What Could Derail the Second-Derivative Thesis

We're bullish on this theme, but intellectual honesty requires laying out the risks.

Discontinuation rates are the biggest concern. Current data suggests 40–50% of GLP-1 users stop the medication within 12 months, often due to cost, side effects (nausea, gastrointestinal issues), or insurance coverage changes. If patients discontinue and regain weight, the associated behavioral changes — gym memberships, activewear spending — may reverse too. The durability of the consumer spending shift depends on long-term adherence, which remains uncertain.

Safety concerns could emerge. GLP-1 drugs have been on the market for less than a decade in their current weight loss formulations, and long-term data beyond 5–7 years is limited. If a significant safety signal emerges (thyroid cancer risk has been flagged in animal studies, though not confirmed in humans), the resulting adoption slowdown would hit second-derivative stocks even harder than pharma, because the fitness and apparel companies have less pricing power to offset volume declines.

Insurance coverage is not guaranteed. Many employers and insurers still do not cover GLP-1 for weight loss (as opposed to diabetes management), and those that do are imposing utilization management barriers — prior authorization, step therapy, annual re-certification. If coverage does not expand as the market expects, the addressable population could plateau at 20–25 million users rather than the 40–100 million that bulls project.

Finally, valuation matters. Several of our second-derivative picks already trade at premium multiples. On Holdings at 42x, Planet Fitness at 30x — these are not cheap stocks. If the GLP-1 tailwind takes longer to materialize in earnings than expected, these names could underperform even as the underlying thesis remains intact.

How We're Tracking This Theme

The GLP-1 second-derivative trade is a data story, not a narrative story. The difference between a good thesis and a great trade is knowing when the data confirms the thesis in real time. Here's what we're monitoring.

Earnings transcripts are the richest signal source. When Life Time Fitness management says “12% of new members cited weight loss medication as a motivating factor,” that's a data point you can track over time. When Garmin calls out “health-motivated new users” as a growing cohort, that's confirmation. When Mondelez guides to lower North American organic growth and blames “shifting consumer preferences,” that's the flip side of the same coin. These are the kinds of signals that DataToBrief extracts automatically from SEC filings and earnings transcripts, flagging GLP-1-related commentary across hundreds of companies so you don't have to read every transcript yourself.

Prescription data from IQVIA and Symphony Health provides monthly fill volumes, which we use as a leading indicator of consumer behavior shifts. Credit card spending data from Earnest Research and Second Measure shows real-time consumer spending patterns by category. Gym membership data from ClassPass and Mindbody tracks fitness participation trends. The thesis is data-rich — you just need to know where to look.

Portfolio Construction: Sizing the GLP-1 Second-Derivative Theme

We treat GLP-1 second-derivative exposure as a thematic overlay, not a concentrated bet. The right approach is to own companies with strong standalone fundamentals that also happen to benefit from the GLP-1 behavioral shift.

Our recommended allocation is 5–10% of an equity portfolio across 3–5 names, with individual position sizes of 1–3%. Within that framework, we think the barbell approach works best: anchor positions in Garmin and Life Time Fitness (strongest standalone fundamentals, most defensible GLP-1 exposure) supplemented by smaller positions in higher-beta names like HIMS and ONON (higher GLP-1 sensitivity, higher valuation risk).

We do not recommend shorting the “losers” as a core strategy. Snack companies can reformulate. Fast food chains can adapt menus. Insurance coverage decisions can change overnight. The long side of the GLP-1 second-derivative trade has better risk-reward than the short side, because the winners have multiple tailwinds while the losers have adaptation options.

The key trigger to size up: oral GLP-1 approval and launch data. If orforglipron shows strong launch uptake in late 2026 or early 2027, the addressable market expansion will be confirmed, and second-derivative names will re-rate. That's when we'd move from 5–10% thematic exposure to 10–15%. For readers tracking how consumer behavior data feeds into sector allocation decisions, our guide on building a systematic stock screening process covers the frameworks we use.

Frequently Asked Questions